Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland

Erkki Soini, Christian Asseburg, Maarit Taiha, Kari Puolakka, Oana Purcaru, Riitta Luosujärvi

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalAdvances in Therapy
Volume34
Issue number10
Pages (from-to)2316-2332
Number of pages17
ISSN0741-238X
DOIs
Publication statusPublished - Oct 2017
MoE publication typeA1 Journal article-refereed

Fields of Science

  • Biological therapies
  • Certolizumab pegol
  • Disease-modifying antirheumatic drugs
  • Health economics
  • Health policies
  • Rheumatoid arthritis
  • Rheumatology
  • MODIFYING ANTIRHEUMATIC DRUGS
  • 5-YEAR FOLLOW-UP
  • QUALITY-OF-LIFE
  • COST-EFFECTIVENESS
  • EULAR RECOMMENDATIONS
  • PRODUCTIVITY COSTS
  • DISEASE-ACTIVITY
  • 2013 UPDATE
  • REGISTER
  • BURDEN
  • 3121 General medicine, internal medicine and other clinical medicine
  • 317 Pharmacy

Cite this